ORIC PHARMACEUTICALS, INC. Operating Lease Right-of-Use Assets
ORIC PHARMACEUTICALS, INC. (ORIC) had Operating Lease Right-of-Use Assets of $6.66 million as of 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-02-23
- 2025-12-31: Operating Lease, Right-of-Use Asset $6.66M.
- 2024-12-31: Operating Lease, Right-of-Use Asset $8.38M.
- 2023-12-31: Operating Lease, Right-of-Use Asset $9.14M.
- 2022-12-31: Operating Lease, Right-of-Use Asset $10.99M; Operating Lease, Right-of-Use Asset as first filed $11.00M.
| Period end | Operating Lease, Right-of-Use Asset | Operating Lease, Right-of-Use Asset as first filed |
|---|---|---|
| 2025-12-31 | $6.66M 10-K · filed 2026-02-23 | |
| 2024-12-31 | $8.38M 10-K · filed 2026-02-23 | |
| 2023-12-31 | $9.14M 10-K · filed 2025-02-18 | |
| 2022-12-31 | $10.99M 10-K · filed 2024-03-11 | $11.00M 10-K · filed 2023-03-16 |
| 2021-12-31 | $11.80M 10-K · filed 2023-03-16 | |
| 2021-09-30 | $12.00M 10-Q · filed 2021-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |